<0> Research and Markets: Company Study of Chongqing Zhifei Biological Products Co., Ltd, 2012 Available Now </0>
<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>
() has announced the addition of the report to their offering.
Chongqing Zhifei Biological Products Co., Ltd (Code:300122.SZ), hereinafter referred to as Zhifei Biological, was established in 1995 with the registered capital of RMB 360 million. Listed on the GEM in Sep. 2010, Zhifei Biological is mainly engaged in the development and management of biological technology. Its prime operating businesses include the R & D, production and sales of vaccines and biological products.
Its independent products are: Group A and Group C Meningococcal Polysaccharide Conjugate Vaccine, Group ACYW135 Meningococcal Polysaccharide Vaccine, Mycobacterium vaccine for Injection, etc, Vaccae has passed GMP certification on Mar.23, 2011; exclusive purchase agent products are: Hib vaccine, Hepatitis A (Live) Vaccine], etc.
3 Revenue Structure
4 Gross Margin
6 R&D and Investment
For more information visit